Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children BRIEF SUMMARY The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome. STUDY DESIGN Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention OFFICIAL TITLE Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children CONDITION Vomiting DETAILED DESCRIPTION There is very little controlled data on the preventative treatment for Cyclic Vomiting Syndrome. The existing evidence consists of small, retrospective clinical series that evaluate symptomatic responses to five medications including cyproheptadine, propranolol, amitriptyline, phenobarbital and pizotifen (n >10). These published data consist of uncontrolled or retrospective reports. In addition, varying inclusion criteria and outcomes (i.e. obtained by family recall) were used in these studies limiting the basis upon which to compare relative effectiveness. During the prospective baseline period, the subject will maintain cyclical vomiting records in which all headache occurrences will be recorded and characterized. (Cyclical vomiting records will be maintained throughout the study). The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome using a prospective design, established diagnostic criteria (ICHD 2004), and defined, objective primary and secondary endpoints. PRIMARY OUTCOME Reduction of cycle frequency as measured by number of days between cycles. SECONDARY OUTCOME Decreased duration of attacks (measured in hours) Decreased intensity of attacks (0-4 point scale; none, mild, moderate, severe, excruciating) Decreased associated symptoms (0-4 point scales; none, mild, moderate, severe, excruciating) Nausea Vomiting Headache Abdominal pain Decreased disability PedMidas Missed school (days per attack) Missed work (parent(s)) (days per attack) Decreased use of acute therapies (e.g. anti-emetics) Decreased emergency department visits. ELIGIBILITY Inclusion Criteria: - - Meet the2004 ICHD Criteria for Cyclical Vomiting. - - 1 vomiting attack lasting > 24 hours duration for 3 consecutive months - - 4-12 years of age. - - If female, subjects must: - 1. be premenarchal or otherwise incapable of pregnancy, or - 2. have practiced one of the following methods of contraception for at least one - month prior to study entry: hormonal contraceptives, spermicide and barrier, - intrauterine device, partner sterility, or - 3. be practicing abstinence and agree to continue abstinence or to use an - acceptable method of contraception (as listed above) should sexual activity - commence. - - Able to take oral medication in tablet form or sprinkle form - - Subjects or their guardians must be willing and able to: a) read and comprehend - written instructions, b) complete the assessment forms, c) return for regular visits, - and d) adhere to medication regimens. - - Subjects (or their legally acceptable representative) must have signed an informed - consent document - Exclusion Criteria - - Have taken topiramate within 14 days prior to the start of the prospective baseline - period. - - Have taken certain medications for cyclical vomiting prophylaxis - - Have progressive neurological disorder or a structural disorder of the brain from - birth, trauma or past infection. - - Subjects who have taken any medications for migraine prophylaxis, within 2 weeks of - the start of the prospective baseline period. - - Subjects starting non-pharmacologic prophylactic approaches (e.g., acupuncture, - biofeedback, chiropractic methods) within 1 month prior to Visit 1. - - Require continuing treatment with anticonvulsant therapy for a non-migraine - condition. - - Significant major psychiatric disorder (e.g., major depression) or subjects receiving - anti-psychotic medication. - - History of attempted suicide or suicidal tendencies. - - History of substance abuse. - - Pregnant or lactating females. - - Have clinically unstable neurological, cardiovascular, gastrointestinal, - musculoskeletal, pulmonary or other disease. - - Have any disease or condition that could compromise the function of those body - systems that could result in altered absorption, excess accumulation, or impaired - metabolism or excretion of the test medications (e.g., abnormal renal and/or hepatic - function). - - Have active liver disease. - - Have received an investigational drug or used an investigational device within 30 - days of study entry. - - Employees of the investigator, study center, or sponsor (i.e., principal - investigator, sub-investigator(s), study coordinators, other study staff, employees, - or contractors of each), with direct involvement in the proposed study or other - studies under the direction of that investigator, study center or sponsor, as well as - family members of the employees or the investigator. GENDER: Both MINIMUM AGE: 4 Years MAXIMUM AGE: 12 Years LOCATION Monarch Medical Research - Child and Adolescent Neurology. Norfolk. Virginia. 23510. United States. FIRST RECEIVED February 1, 2006 VERIFICATION DATE April 2007 LAST CHANGED January 5, 2011 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Sponsored by: Monarch Medical Research
Phase: Phase IV , Start Date: Mar 20, 2006
Clinical Trials – Jan 5, 2011
Free

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children


BRIEF SUMMARY

The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.
STUDY DESIGN

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
OFFICIAL TITLE

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children
CONDITION

Vomiting
DETAILED DESCRIPTION

There is very little controlled data on the preventative treatment for Cyclic Vomiting Syndrome. The existing evidence consists of small, retrospective clinical series that evaluate symptomatic responses to five medications including cyproheptadine, propranolol, amitriptyline, phenobarbital and pizotifen (n >10). These published data consist of uncontrolled or retrospective reports. In addition, varying inclusion criteria and outcomes (i.e. obtained by family recall) were used in these studies limiting the basis upon which to compare relative effectiveness. During the prospective baseline period, the subject will maintain cyclical vomiting records in which all headache occurrences will be recorded and characterized. (Cyclical vomiting records will be maintained throughout the study). The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome using a prospective design, established diagnostic criteria (ICHD 2004), and defined, objective primary and secondary endpoints.
PRIMARY OUTCOME

Reduction of cycle frequency as measured by number of days between cycles.
SECONDARY OUTCOME

Decreased duration of attacks (measured in hours) Decreased intensity of attacks (0-4 point scale; none, mild, moderate, severe, excruciating) Decreased associated symptoms (0-4 point scales; none, mild, moderate, severe, excruciating) Nausea Vomiting Headache Abdominal pain Decreased disability PedMidas Missed school (days per attack) Missed work (parent(s)) (days per attack) Decreased use of acute therapies (e.g. anti-emetics) Decreased emergency department visits.
ELIGIBILITY

Inclusion Criteria: - - Meet the2004 ICHD Criteria for Cyclical Vomiting. - - 1 vomiting attack lasting > 24 hours duration for 3 consecutive months - - 4-12 years of age. - - If female, subjects must: - 1. be premenarchal or otherwise incapable of pregnancy, or - 2. have practiced one of the following methods of contraception for at least one - month prior to study entry: hormonal contraceptives, spermicide and barrier, - intrauterine device, partner sterility, or - 3. be practicing abstinence and agree to continue abstinence or to use an - acceptable method of contraception (as listed above) should sexual activity - commence. - - Able to take oral medication in tablet form or sprinkle form - - Subjects or their guardians must be willing and able to: a) read and comprehend - written instructions, b) complete the assessment forms, c) return for regular visits, - and d) adhere to medication regimens. - - Subjects (or their legally acceptable representative) must have signed an informed - consent document - Exclusion Criteria - - Have taken topiramate within 14 days prior to the start of the prospective baseline - period. - - Have taken certain medications for cyclical vomiting prophylaxis - - Have progressive neurological disorder or a structural disorder of the brain from - birth, trauma or past infection. - - Subjects who have taken any medications for migraine prophylaxis, within 2 weeks of - the start of the prospective baseline period. - - Subjects starting non-pharmacologic prophylactic approaches (e.g., acupuncture, - biofeedback, chiropractic methods) within 1 month prior to Visit 1. - - Require continuing treatment with anticonvulsant therapy for a non-migraine - condition. - - Significant major psychiatric disorder (e.g., major depression) or subjects receiving - anti-psychotic medication. - - History of attempted suicide or suicidal tendencies. - - History of substance abuse. - - Pregnant or lactating females. - - Have clinically unstable neurological, cardiovascular, gastrointestinal, - musculoskeletal, pulmonary or other disease. - - Have any disease or condition that could compromise the function of those body - systems that could result in altered absorption, excess accumulation, or impaired - metabolism or excretion of the test medications (e.g., abnormal renal and/or hepatic - function). - - Have active liver disease. - - Have received an investigational drug or used an investigational device within 30 - days of study entry. - - Employees of the investigator, study center, or sponsor (i.e., principal - investigator, sub-investigator(s), study coordinators, other study staff, employees, - or contractors of each), with direct involvement in the proposed study or other - studies under the direction of that investigator, study center or sponsor, as well as - family members of the employees or the investigator.
GENDER: Both
MINIMUM AGE: 4 Years
MAXIMUM AGE: 12 Years
LOCATION

Monarch Medical Research - Child and Adolescent Neurology. Norfolk. Virginia. 23510. United States.
FIRST RECEIVED

February 1, 2006
VERIFICATION DATE

April 2007
LAST CHANGED

January 5, 2011

Loading next page...
1 Page
/lp/clinical-trials/topiramate-for-the-prophylactic-treatment-of-cyclic-vomiting-syndrome-WCpLDqswU0
Clinical Trials
Clinical Trials
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial